eMedicine Specialties > Infectious Diseases > Viral Infections
Coxsackieviruses: Follow-up
Updated: Dec 21, 2009
Follow-up
Further Inpatient Care
- Severe aseptic meningitis and/or encephalitis, seizures, myopericarditis, and heart failure require admission for workup and treatment. Antibiotics may be used until bacterial meningitis is ruled out. Supportive inpatient or intensive care may be necessary for severe cases.
Further Outpatient Care
- No outpatient care, other than usual follow-up care, is required for patients with mild symptoms.
Inpatient & Outpatient Medications
- Inpatient medications indicated are based on the patient's presentation at admission (eg, phenytoin for seizure prophylaxis and/or suppression in patients with aseptic meningitis/encephalitis, digoxin in patients with heart failure).
- Antipyretics (eg, acetaminophen) for fever and NSAIDs for pain should be adequate in patients with mild symptoms who do not require hospital admission.
Transfer
- Transfer to a tertiary facility may be necessary for specialized consultations or surgeries.
Deterrence/Prevention
- Minimize respiratory contact with the infected patient if possible.
- To prevent further transmission, strict handwashing should be encouraged and sharing of towels should be avoided.
Complications
- See History and Physical, which discuss the many presentations of coxsackievirus infections.
- Complications of aseptic meningitis include lethargy, seizures, coma, and movement disorders (5-10%).
- Complications of myopericarditis include pericardial effusion, arrhythmia, heart block, valvular dysfunction, and dilated cardiomyopathy.
- Rare complications of acute hemorrhagic conjunctivitis (AHC) include keratitis and motor paralysis.
Prognosis
- In general, the prognosis is very good, with 90% of patients having no symptoms or experiencing mild, self-limited, nonspecific febrile illnesses or rashes.
Patient Education
- Patients should be aware of the need for good hygiene practices to avoid transmission.
- Patients need to be reassured that they have a self-limited viral illness that does not require any antibiotics for treatment.
Miscellaneous
Medicolegal Pitfalls
- Failure to diagnose bacterial meningitis may result in a poor outcome. All patients who have symptoms or CSF profiles suggestive of bacterial meningitis (WBC count >1000 cells/μL, neutrophil predominance, hypoglycorrhachia, elevated protein levels) should be managed with antibiotics until cultures are negative for bacteria. Patients with severe courses and encephalitis should be evaluated for alternative causes of encephalitis (herpes simplex virus, arboviruses) that may be treatable.
- Failure to diagnose myocarditis promptly may result in cardiovascular complications (eg, severe heart failure).
- Failure to obtain appropriate consultations early (eg, neurologist, neurosurgeon, cardiologist, cardiothoracic surgeon) could lead to delays in definitive management.
Special Concerns
- In addition to fecal-oral and respiratory transmission, be aware that spread of coxsackieviruses via fomites is possible; therefore, appropriate actions should be taken. Careful handwashing and disposal of contaminated objects should decrease the spread of enteroviruses.
More on Coxsackieviruses |
| Overview: Coxsackieviruses |
| Differential Diagnoses & Workup: Coxsackieviruses |
| Treatment & Medication: Coxsackieviruses |
Follow-up: Coxsackieviruses |
| References |
| Further Reading |
| « Previous Page |
References
Khetsuriani N, Lamonte A, Oberste MS, et al. Neonatal enterovirus infections reported to the national enterovirus surveillance system in the United States, 1983-2003. Pediatr Infect Dis J. Oct 2006;25(10):889-93. [Medline].
King RL, Lorch SA, Cohen DM, et al. Routine cerebrospinal fluid enterovirus polymerase chain reaction testing reduces hospitalization and antibiotic use for infants 90 days of age or younger. Pediatrics. Sep 2007;120(3):489-96. [Medline].
Schiff GM, Sherwood JR. Clinical activity of pleconaril in an experimentally induced coxsackievirus A21 respiratory infection. J Infect Dis. Jan 2000;181(1):20-6. [Medline].
Brunetti L, DeSantis ER. Treatment of viral myocarditis caused by coxsackievirus B. Am J Health Syst Pharm. Jan 15 2008;65(2):132-7. [Medline].
Yue-Chun L, LiSha G, Jiang-Hua R, Peng-Lin Y, Jia-Feng L, Ji-Fei T, et al. Protective effects of carvedilol in murine model with the coxsackievirus B3-induced viral myocarditis. J Cardiovas Pharmacol. Jan/2008;51:92-98. [Medline].
Shi L, Xiong H, He J, et al. Antiviral activity of arbidol against influenza A virus, respiratory syncytial virus, rhinovirus, coxsackie virus and adenovirus in vitro and in vivo. Arch Virol. 2007;152(8):1447-55. [Medline].
Ang LW, Koh BK, Chan KP, Chua LT, James L, Goh KT. Epidemiology and control of hand, foot and mouth disease in Singapore, 2001-2007. Ann Acad Med Singapore. Feb 2009;38(2):106-12. [Medline].
Bergman I, Painter MJ, Wald ER, et al. Outcome in children with enteroviral meningitis during the first year of life. J Pediatr. May 1987;110(5):705-9. [Medline].
Berlin LE, Rorabaugh ML, Heldrich F, et al. Aseptic meningitis in infants < 2 years of age: diagnosis and etiology. J Infect Dis. Oct 1993;168(4):888-92. [Medline].
Cheung CT, Deisher TA, Luo H, et al. Neutralizing anti-4-1BBL treatment improves cardiac function in viral myocarditis. Lab Invest. Jul 2007;87(7):651-61. [Medline].
Dagan R, Jenista JA, Menegus MA. Association of clinical presentation, laboratory findings, and virus serotypes with the presence of meningitis in hospitalized infants with enterovirus infection. J Pediatr. Dec 1988;113(6):975-8. [Medline].
Dagan R, Menegus MA. A combination of four cell types for rapid detection of enteroviruses in clinical specimens. J Med Virol. Jul 1986;19(3):219-28. [Medline].
Dulbecco R, Ginsberg H. Virology. 2nd ed. 1988:207-209.
Enterovirus surveillance--United States, 2002-2004. MMWR Morb Mortal Wkly Rep. Feb 17 2006;55(6):153-6. [Medline].
Jaïdane H, Hober D. Role of coxsackievirus B4 in the pathogenesis of type 1 diabetes. Diabetes Metab. Dec 2008;34(6 Pt 1):537-48. [Medline].
Jenista JA, Powell KR, Menegus MA. Epidemiology of neonatal enterovirus infection. J Pediatr. May 1984;104(5):685-90. [Medline].
Levinson W, Jawetz E. Medical Microbiology & Immunology: Examination & Board Review. 6th ed. New York, NY: McGraw Hill Text; 2000:238-239.
Modlin JF. Coxsackieviruses, echoviruses, and newer enteroviruses. In: Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases. 5th ed. Philadelphia, Pa: Churchill-Livingstone; 2000:1904-1919.
Moore M. Centers for Disease Control. Enteroviral disease in the United States, 1970-1979. J Infect Dis. Jul 1982;146(1):103-8. [Medline].
Morens DM, Pallansch MA. Epidemiology. Human Enterovirus Infections. 1995;1.
Pallansch MA, Anderson LJ. Coxsackievirus, echovirus, and other enteroviruses. In: Gorbach SL, ed. Infectious Diseases. 2nd ed. Philadelphia, Pa: WB Saunders Co; 1998:2164-2170.
Piqueur MA, Verstrepen WA, Bruynseels P, Mertens AH. Improvement of a real-time RT-PCR assay for the detection of enterovirus RNA. Virol J. Jul 7 2009;6:95. [Medline].
Rantala H, Uhari M. Occurrence of childhood encephalitis: a population-based study. Pediatr Infect Dis J. Jul 1989;8(7):426-30. [Medline].
Richer MJ, Horwitz MS. Coxsackievirus infection as an environmental factor in the etiology of type 1 diabetes. Autoimmun Rev. Jun 2009;8(7):611-5. [Medline].
Rorabaugh ML, Berlin LE, Heldrich F, et al. Aseptic meningitis in infants younger than 2 years of age: acute illness and neurologic complications. Pediatrics. Aug 1993;92(2):206-11. [Medline].
Rotbart HA. Pleconaril therapy of potentially life-threatening enterovirus infections. 36th Annual Meeting of the Infectious Disease Society of America. 1998.
Rotbart HA. Pleconaril treatment of enterovirus and rhinovirus infections. Infect Med. 2000;17:488.
Rotbart HA. Treatment of picornavirus infections. Antiviral Res. Feb 2002;53(2):83-98. [Medline].
Rotbart HA, Ahmed A, Hickey S, et al. Diagnosis of enterovirus infection by polymerase chain reaction of multiple specimen types. Pediatr Infect Dis J. Apr 1997;16(4):409-11. [Medline].
Rotbart HA, McCracken GH Jr, Whitley RJ, et al. Clinical significance of enteroviruses in serious summer febrile illnesses of children. Pediatr Infect Dis J. Oct 1999;18(10):869-74. [Medline].
Rotbart HA, Webster AD. Treatment of potentially life-threatening enterovirus infections with pleconaril. Clin Infect Dis. Jan 15 2001;32(2):228-35. [Medline].
Sauter P, Hober D. Mechanisms and results of the antibody-dependent enhancement of viral infections and role in the pathogenesis of coxsackievirus B-induced diseases. Microbes Infect. Apr 2009;11(4):443-51. [Medline].
Sawyer MH, Holland D, Aintablian N, et al. Diagnosis of enteroviral central nervous system infection by polymerase chain reaction during a large community outbreak. Pediatr Infect Dis J. Mar 1994;13(3):177-82. [Medline].
Tebruegge M, Curtis N. Enterovirus infections in neonates. Semin Fetal Neonatal Med. Aug 2009;14(4):222-7. [Medline].
Voroshilova MK, Chumakov MP. Poliomyelitis-like properties of AB-IV Coxsackie A7 group of viruses. Prog Med Virol. 1959;2:106.
Weller TH, Enders JF, Buckingham M, et al. The etiology of epidemic pleurodynia: a study of two viruses isolated from a typical outbreak. J Immunol. Sep 1950;65(3):337-46. [Medline].
Further Reading
Clinical trials
Urinary Excretion of Enteroviruses From Children With a Presumed Enteroviral Infection
Keywords
coxsackieviruses, coxsackie viruses, coxsackie virus A, coxsackievirus A, hand-foot-and-mouth disease, hand-foot-mouth disease, HFM disease, vesicular stomatitis with exanthem, coxsackievirus B, coxsackie virus B, Bamle disease, Bornholm disease, Daae disease, Sylvest disease, benign dry pleurisy, epidemic pleurodynia, devil's grip, devil's grippe, diaphragmatic pleurisy, epidemic benign dry pleurisy, epidemic diaphragmatic pleurisy, epidemic myalgia, epidemic myositis, myositis epidemica acuta, epidemic transient diaphragmatic spasm, aseptic meningitis, acute hemorrhagic conjunctivitis, AHC, enteroviral infection
Follow-up: Coxsackieviruses